Condition

Schizophrenic Disorders

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting0
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
Interest of EMDR Schizophrenic DisordersNCT05164289 · 2021-12-10
TERMINATED
Neuropsychological Assessment of Remediation for Cognitive Impairments in SchizophreniaNCT04608032 · 2020-09-08
UNKNOWN
Have a Good Grasp of the Worldthe WorldNCT02655172 · 2016-05-24
COMPLETED
Sodium Butyrate For Improving Cognitive Function In SchizophreniaNCT02654405 · 2016-04-01
WITHDRAWN
Upside Down, Give me the HandleNCT02544516 · 2014-04-01
COMPLETED
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaNCT01606436 · 2012-06-01
COMPLETED
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)NCT01729650 · 2012-06-01
COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic SchizophreniaNCT00960219 · 2009-04-01
COMPLETED
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant SchizophreniaNCT01279213 · 2009-01-01
COMPLETED
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible DoseNCT00660595 · 2008-09-01
TERMINATED
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to RisperidoneNCT00600756 · 2008-01-01
COMPLETED
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory HallucinationsNCT02525315 · 2007-06-01
COMPLETED
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.NCT00488319 · 2007-06-01
COMPLETED
The Psychiatric Rehabilitation Approach to Weight LossNCT00572247 · 2007-01-01
COMPLETED
Sarcosine Preventive Therapy for Individuals At High Risk for SchizophreniaNCT00276263 · 2006-08-01
WITHDRAWN
Sarcosine or D-Serine Add-on Treatment for Chronic SchizophreniaNCT00491569 · 2005-01-01
COMPLETED
Sarcosine (N-Methylglycine) Monotherapy for SchizophreniaNCT00328276 · 2004-12-01
COMPLETED
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderNCT00088465 · 2004-08-01
COMPLETED
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With SchizophreniaNCT00088491 · 2004-06-01
COMPLETED
Assessment of a Weight Management Program for Weight Gain in Patients With SchizophreniaNCT00485823 · 2002-12-01
COMPLETED
Psychological Intervention for Relapse Prevention in First Episode SchizophreniaNCT00161408 · 2000-12-01
UNKNOWN

Common interventions

Leading sponsors

Trial status mix

COMPLETED15
TERMINATED2
UNKNOWN2
WITHDRAWN2

Phase mix

NA6
PHASE26
PHASE36
PHASE42
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.